anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The systemic manifestations of coronavirus disease 2019 (COVID-19) include hyperinflammatory reactions in various organs. Recent studies showed evidence for the frequent involvement of central nervous system in affected patients; however, little is known about clinical features of cerebrovascular diseases in childhood-onset COVID-19.
CASE PRESENTATION: A 10-year-old boy recovered from SARS-CoV-2 infection without complication. On 14 days after infection, he presented with loss of consciousness. A head computed tomography detected a ruptured cerebral aneurysm at the left posterior cerebral artery accompanying subarachnoid hemorrhage (SAH). Immediate surgical intervention did not rescue the patient, resulting in the demise 7 days after admission. Serological and genetic tests excluded the diagnosis of vasculitis and connective tissue disorders. Retrospective analysis showed markedly higher levels of interleukin (IL)-1β, IL-6 and IL-8 in the cerebrospinal fluid than the serum sample concurrently obtained. A review of literature indicated that adult patients with COVID-19 have a risk for the later development of SAH during the convalescent phase of COVID-19.
CONCLUSIONS: SAH is a severe complication of COVID-19 in children and adults who have asymptomatic cerebrovascular aneurysms. The markedly high levels of cytokines detected in the cerebrospinal fluid suggested that intracranial hyperinflammatory condition might be one of the possible mechanisms involved in the rupture of a preexisting cerebrovascular aneurysms.
PROBLEM TO BE SOLVED: To obtain the subject compound improved in hygroscopicity and useful in cosmetics, medicaments and the like, at about room temperature easily and in a short time by crystallization using an organic solvent as poor solvent from an aqueous solution with the molar ratio of sodium ion to specific ascorbic phosphoric ester ion below a specific level. SOLUTION: This compound is obtained by crystallization from an aqueous solution with the molar ratio of sodium ion to L-ascorbic-2-phosphoric ester ion being <3, pref. 2.70-2.99 using as poor solvent an organic solvent, pref. methanol and/or acetone, pref. at 0-40 deg.C; wherein the above aqueous solution is pref. 1-15 w/v in the concentration of the L-ascorbic-2-phosphoric ester sodium salt, and it is preferable that the amount of the above organic solvent to be used is such as to be 50-80 v/v in its concentration in the solution after finishing addition of the organic solvent to the above aqueous solution.
A method for fabricating an article of manufacture includes forming a plurality of layers of the article based on a digital model of the article. Each layer of the plurality of layers may be formed by depositing at least two materials that differ from one another. The at least two materials may be deposited separately or simultaneously. The at least two materials may define separate regions of the layer and, thus, define distinct features of the article, and/or the at least two materials may be mixed or one of the materials may be dispersed throughout the other to define a blended zone in the layer. Blended zones of adjacent layers may be superimposed to define three-dimensional blended zones. A blended zone may be graded to provide transition between separate regions of the article that are formed from two or more different materials. Articles fabricated by such processes are also disclosed.
Use of agomelatin or its hydrates, crystalline forms or additive salts of an acid or a base, is claimed for obtaining a drug for treating bipolar disorders. An independent claim is included for an association containing agomelatin and a thymoregulator agent. ACTIVITY : Neuroleptic; Antidepressant; Cardiovascular-Gen.; Hypnotic; Sedative; Anorectic; Eating-Disorders-Gen. In a test, the ability of agomelatin to treat bipolar disorder was tested in human patients. The results showed that 81% of the patients showed positive improvement. MECHANISM OF ACTION : Melatonergic receptor agonist; 5-Hydroxytryptamine 2C receptor antagonist.
The placebo comparator treatment will consist of 10-15 g/day placebo powder, that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks to mirror the treatment arms. The study will end after the second time-point sample collection at 4 weeks.
PCT No. PCT/DK90/00228 Sec. 371 Date Mar. 20, 1992 Sec. 102(e) Date Mar. 20, 1992 PCT Filed Sep. 3, 1990 PCT Pub. No. WO91/03487 PCT Pub. Date Mar. 21, 1991.Compounds of formula (I), wherein R1 is selected from the group consisting of an alkyl group, an aralkyl group, an alkenyl group, a cycloalkyl group, in which the alkyl, aralkyl, alkenyl or cycloalkyl group is unsubstituted or substituted with one or more substituents selected from the group consisting of a halogen atom, e.g. Cl or Br, a hydroxyl group or a straight or branched-chain alkoxy group containing from 1 to 6 carbon atoms; and the pharmaceutically acceptable acid addition salts thereof. Such compounds are prodrugs of TRH and are characterized by having a higher lipophilicity than TRH and possessing a high resistance toward degradation by TRH-inactivating enzymes. Such compounds will after administration be converted into TRH.
The aim of the study is to refine, elaborate, and pilot a brief intervention for adult patients following a suicide attempt provided during hospitalization in an acute medical setting, and will be addressed with a sample of cases (N = 40) from Harborview. The participants will be randomized into one of two groups: those that receive the intervention and those that do not. All participants will complete a battery of assessments The intervention is based on the theory of teachable moments, wherein timing in proximity to injury and appropriate treatment setting provide a unique opportunity to create patient behavioral change. The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, and safety planning. A guide to delivering the intervention has been completed and may undergo changes throughout the study. Adherence measures will be developed in order to assess the degree to which the clinician accurately provided the brief intervention without including additional therapeutic elements or leaving out elements required in the intervention guide. Best methods for integrating the brief intervention into services provided on medical and surgical units will be determined, as well.
At baseline, each subject will complete a demographic questionnaire (age, gender, date of type 1 diabetes diagnosis, current medications, other medical conditions, number of episodes of severe hypoglycemia and diabetic ketoacidosis since diagnosis of type 1 diabetes) and an anthropometric data form (height, weight, body mass index). A baseline stool sample will be collected at home. One tablespoon of stool will be placed in a pre-labelled sterile conical tube, placed in a biohazard bag and stored in the home freezer (-20°C). Stool samples will be brought to the laboratory on ice within 3 days from collection and stored at -80°C until analysis. Subjects will have a baseline blood sample drawn for HbA1c, C-peptide, and inflammatory markers (IL-6, IFN-γ, TNF-α, and IL-10), GLP1 and GLP2. An intestinal permeability test will be performed as described below.

Subjects will be randomized to receive either placebo (maltodextrin 3.3 g orally/ day) or prebiotic fiber (1:1 oligofructose: inulin 8 g orally /day). Both are approved as food ingredients in Canada and not regulated as natural health products. Dr. Reimer has a 'no objection' letter from Health Canada and has previously used these in a clinical trial (14).

Both prebiotic fiber and placebo come in a powder form in a pre-measured packet. Subjects will be instructed to mix the packet with 250 mL water until dissolved and to take 15-20 minutes prior to their evening meal. For the first two weeks, subjects will be asked to only take half of the dose in order to minimize GI side effects and then they will take the full dose for the remaining 10 weeks. Subjects will be asked to record any diabetes related adverse reactions (ie. severe hypoglycemia and diabetic ketoacidosis). At the end of the 12 weeks (3months), subjects will be asked to submit a second stool sample and repeat baseline blood tests and intestinal permeability testing. Subjects will be asked to return any remaining packets of placebo or prebiotic in order to assess for compliance. A third stool sample, intestinal permeability testing and blood sample (HbA1c, C-peptide, inflammatory markers (IL-6, IFN-γ, TNF-α, and IL-10), GLP1 and GLP2) will be done at 6 months follow up. Telephone contact from a member of the research team (research assistant or PI) will occur monthly to encourage compliance and recording of adverse reactions.
The subject health monitoring system is designed to supplement in an embodiment of the invention the health care efforts in caring for patients confined to their homes. The system may also be utilized within a facility such as a nursing home for monitoring patients within the home. The system integrates components distributed between a hospital and/or a central monitoring office to provide improved monitoring of these patients. The system provides for the translation of initiating orders into a computerized format. The system further provides for the programming of a patient monitoring unit at the remote site with the specific protocols consistent with the diagnoses of the doctor, as indicated on the initiating order. The system further provides for computerized training and prompting of the patient to assure their compliance with the initiating orders. Additionally, the system provides for intelligent communication between the remote site and the central office when appropriate. The system provides for the transmission of relevant data from the remote site to the central office when a critical event occurs. The system also provides for notification and graphical presentment to the doctor of trending of the patients biometric parameters. The trending parameters computed and presented to the doctor are disease specific, thus making for a more timely response. Finally, the system provides for the accumulation of a statistically normalized database correlating various medications as to their efficacy, duration, and side effects.
PURPOSE: In the field of health sciences gender is often confused with biological sex (male/female) or reduced to a dichotomous classification (masculinity/femininity). The concepts of sex and gender interact with each other, but they are not equivalent. According to Sandra Bem four gender typologies can be established (androgynous, masculine, feminine and undifferentiated). A relationship has been shown to exist between gender and health. Yet, there is little evidence as to the relationship between gender typologies and adherence to the Mediterranean diet. The aim of this research is to evaluate the association between Bem's gender typologies and adherence to the Mediterranean diet.
METHODS: Mediterranean Diet Adherence Screener (MEDAS) and Bem's gender typologies were the main variables. Sex, age, socioeconomic status (SES), body mass index (BMI) and obesity were analyzed as covariates.
RESULTS: Multilevel multivariate analysis showed that androgynous typology was associated with increased adherence to Mediterranean diet (β = 0.46 (SE 0.21), p = 0.033), adjusting by covariates, in a university population in Spain. Moreover, this was not the case with masculinity or femininity typologies.
CONCLUSION: Thus, the results of this study suggest (1) that androgynous typology is not only associated with better mental health but also with healthy/healthier lifestyles, and (2) the complexity of the relationship between sex-gender and health would advise researchers avoid dichotomies such as male/female or masculinity/femininity.
The present invention relates in part to turmeric extracts that are useful for treating or preventing neurodegenerative disorders. Another aspect of the invention relates in part to turmeric extracts that are useful for treating or preventing inflammatory disorders. In some embodiments, the extracts comprise at least one compound selected from the group consisting of 0.01 to 1% by weight of bamosamine, 0.01 to 5% by weight of echinaxanthol, 0.1 to 10% by weight of bisdemethoxycurcumin, 0.01 to 1% by weight of daphniyunnine E and 0.1 to 80% by weight of curcumin. Another aspect of the invention relates to pharmaceutical compositions comprising the aforementioned extracts. Another aspect of the invention relates to methods of treating or preventing neurodegenerative disorders comprising administering to a subject in need thereof an effective amount of the aforementioned extracts or compositions. Another aspect of the invention relates to methods of making the aforementioned extracts.
Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases. Drawbacks, including cytology's low reproducibility and requirement for short screening intervals, raise the need for alternative triage methods. Here we used an innovative triage technique, the WID-qCIN test, to assess the DNA methylation of human genes DPP6, RALYL and GSX1 in a real-life cohort of 28,017 women aged ≥30 years who attended CC screening in Stockholm between January and March 2017. In the analysis of all 2,377 HPV-positive samples, a combination of WID-qCIN (with a predefined threshold) and HPV16 and/or HPV18 (HPV16/18) detected 93.4% of cervical intraepithelial neoplasia grade 3 and 100% of invasive CCs. The WID-qCIN/HPV16/18 combination predicted 69.4% of incident cervical intraepithelial neoplasia grade 2 or worse compared with 18.2% predicted by cytology. Cytology or WID-qCIN/HPV16/18 triage would require 4.1 and 2.4 colposcopy referrals to detect one cervical intraepithelial neoplasia grade 2 or worse, respectively, during the 6 year period. These findings support the use of WID-qCIN/HPV16/18 as an improved triage strategy for HPV-positive women.
This is a multicenter real-world observational study analyzing data on the use of the DBLG1 system in patients with T1D treated in the participating centers in Belgium. Data from patients with T1D who start(ed) with the DBLG1 between may-01 2022 up to and including August-01 2023 will be analyzed. Data will be collected during clinical routine follow-up from electronic medical records, questionnaires, standard of care laboratory tests and CGM-data. Baseline data from before start (up to -12 months) of the DBLG1 system and follow-up data at 4, 8, 12, 16, 20 and 24 months will be analyzed. There are no medical interventions, nor extra visits or laboratory tests planned outside normal clinical routine. Glycemic control and patient-reported outcomes during follow-up will be compared with glycemic control and patient-reported outcome data at baseline.
In this arm, the subjects will receive the intervention of regular rehabilitation program prescribed by physician of rehabilitation. On Day1, Day2, and Day4, the subjects will receive assessments before and after each interventions. After total treatments finishing, the subjects will receive assessments on Day8 and Day15.
OBJECTIVE: We aimed to explore the effectiveness of the modified tubularized incised plate urethroplasty (Snodgrass Technique) in hypospadias surgery.
PATIENTS AND METHODS: A study was conducted on 50 pediatric patients with hypospadias treated in our hospital from May 2020 to May 2023. The patients were divided into two groups based on the condition of their urethral plate; 22 patients were included in the study group and 28 patients were included in the control group. The control group underwent the traditional Snodgrass technique, while the study group received the modified Snodgrass technique. The two groups were compared in terms of treatment efficacy, preoperative and postoperative 6-month Hypospadias Objective Scoring Evaluation (HOSE) scores, surgical data, and postoperative complications.
RESULTS: The operation time for the study group was longer than that of the control group, and the intraoperative blood loss was less, but the differences were not statistically significant (p > 0.05). The success rate of surgery in the study group was 95.45% (21/22), compared to 71.43% (20/28) in the control group, showing a statistically significant difference (p < 0.05). The maximum urinary flow rate at 3 and 6 months postoperatively was significantly higher in the study group than in the control group (p < 0.05). The time to maximum flow (TQmax) and post-void residual (PVR) at 3 and 6 months postoperatively were significantly lower in the study group (p < 0.05). A total of 3 patients in the cohort developed urethral fistulas, all between 0.10 cm x 0.10 cm and 0.15 cm x 0.15 cm in size. By instructing the patients to apply pressure to the fistula during urination, all fistulas closed between 3 and 6 months postoperatively. The incidence of postoperative complications was 4.55% in the study group and 28.57% in the control group, a difference that was statistically significant (p < 0.05).
CONCLUSIONS: The modified Snodgrass technique shows significant therapeutic effectiveness in hypospadias surgery, substantially increasing the success rate and reducing postoperative complications in pediatric patients, making it suitable for widespread application.
Very few literatures reported the clinical use of microbiota or bacteria for brain diseases. The most effective strategy for reconstruction of gut microbiota should be fecal microbiota transplantation (FMT). This study aims to evaluate the efficacy and safety of FMT for epilepsy. Patients were diagnosed as epilepsy by electroencephalogram (EEG) and MRI and clinical data when the study began and thent received repeated FMT with fecal from healthy donors.The antiepileptic medication regimen of patients remained unchanged after FMT. The primary outcome measure was the frequency of the seizures. Secondary outcome measure were the 50% response rate.

.
A coating composition for pills and tablets comprises particles of purified arsenic-free shellac suspended in an aqueous alcoholic solution of methyl cellulose, hydroxyethyl cellulose or sodium carboxymethylcellulose.  The shellac may be present in a concentration of 40-100% by weight of the cellulose derivative, and the latter may be present in a concentration of from 5-10% by weight of the composition when of low viscosity (less than 100 cps.), 3-5% when of medium viscosity and 2-3% when of high viscosity (over 1,500 cps.).  The alcohol may be ethanol, but other alcohols may be used, e.g. methanol or isopropanol.  A plasticizer, e.g. propylene glycol, glycerin, or polyethylene glycol of molecular weight 200-600, may be added in an amount of 1-3 g. per 100 g. of composition.  Other specified plasticizers include cotton seed oil and corn oil. Conventional colouring, sweetening, flavouring and opacifying agents may be added.ALSO:A coating composition for pills and tablets comprises particles of purified arsenic-free shellac suspended in an aqueous alcoholic solution of methyl cellulose, hydroxyethyl cellulose or sodium carboxymethylcellulose.  The shellac may be present in a concentration of 40-100% by weight of the cellulose derivative, and the latter may be present in a concentration of from 5-10% by weight of the composition when of low viscosity (less than 100 c.p.s.), 3-5% when of medium viscosity and 2-3% when of high viscosity (over 1500 c.p.s.).  The alcohol may be ethanol, but other alcohols may be used, e.g. methanol or isopropanol.  A plasticizer, e.g. propylene glycol, glycerine, or polyethylene glycol of molecular weight 200-600, may be added in an amount of 1-3 g. per 100 g. of composition.  Other specified plasticizers include cottonseed oil and corn oil.  Conventional colouring, sweetening, flavouring and opacifying agents may be added.
Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
The invention relates to a traditional Chinese medicine ointment used for treating leucoderma, and a preparation method thereof. The traditional Chinese medicine ointment comprises following raw materials, herba siegesbeckiae, fructus psoraleae, zaocys dhumnade, cinnamon, crocus sativus and radix astragali. The traditional Chinese medicine ointment is capable of adjusting immunologic functions, activating tyrosinase, promoting growth of black cells, improving light sensitivity, promoting blood circulation and removing blood stasis, and improving microcirculation. The traditional Chinese medicine ointment is developed based on traditional Chinese medicine treatment which is based on syndrome differentiation, and by combination of modern latest scientific research achievements. The traditional Chinese medicine ointment used for treating leucoderma, and the preparation method thereof are provided in the invention. The traditional Chinese medicine ointment possesses characteristics of accurate curative effects, safety and convenience, and low cost, and no toxic or side effect is caused.
<P>PROBLEM TO BE SOLVED: To provide a blood circulation-improving composition having excellent blood circulation-improving effect and further having high safety and practicality and being widely useable for beverages and foods, feed, quasi-drugs, medicines, etc.  <P>SOLUTION: The blood circulation-improving composition comprises ellagitannin as an active ingredient. The blood circulation-improving composition comprises at least one selected from a group consisting of elaeocarpusin, chebulagic acid, geraniin and corilagin as ellagitannin as an active ingredient. These ingredients are derived from natural plants having actual results taken in human bodies over a long period, e.g, amla and are free from fear inducing strong adverse action even if they are taken in human bodies in large amounts and have high safety. Therefore, the composition has high practicality and can widely be used for beverages and foods, feed, quasi-drugs, medicines, etc.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The control study product is identical in packaging and formulation except that none of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485 and Pediococcus acidilactici CECT7483 (probiotic bacteria) are present. The Control product contains maltodextrin (E1400, qs) only, in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
Albumin infusions have been used for expansion of the plasma volume for more than 60 years, not only in the operating room, but also in trauma and sepsis. However, there is an ongoing debate whether albumin is good or bad for the patient compared to other intravenous fluids, in different situations. Our research program aims at exploring this issue, starting by describing how the body handles the endogenous albumin in connection with severe inflammation. The final goal is to improve fluid treatment for these patients.

Plasma albumin is often decreased in inflammation. However, the underlying mechanisms are not well described. Two aspects of albumin kinetics will be covered in this study by measurements immediately before and two days after major abdominal surgery, that will serve as a model for generalized inflammation. Albumin fractional synthesis rate will be determined by the incorporation of deuterium labelled phenylalanine into plasma albumin. Albumin distribution will be measured as transcapillary escape rate of radioiodinated albumin. By assessment of P-albumin and plasma volume it will be possible to calculate albumin absolute rate of synthesis and albumin absolute flux from the central compartment, respectively.